Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408589 · ClinicalTrials.gov registry record · Phase 1
A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol
A Phase 1 study, sponsored by University of Colorado, Boulder.
- Terminated
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT01408589 is a Phase 1 study that was terminated before completion, run by University of Colorado, Boulder. The registered enrollment target is 86 participants.
The verdict
NCT01408589, a Phase 1 study, was terminated before completion, sponsored by University of Colorado, Boulder.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This two-stage study will examine the effects of a 5 day course of atomoxetine (placebo, 40, 60 or 80 mg/day; Strattera) (a selective NE transporter (NET) inhibitor) on alcohol-elicited craving and sensitivity to alcohol. The novelty of this study is that of atomoxetine and the fact that it targets NET, neither of which has heretofore been examined in the context of alcohol dependence. It is hopeful that this pilot study, of 86 total individuals, will provide the PI with sufficient preliminary data to submit a subsequent R01 application to study atomoxetine and the involvement of specific single nucleotide polymorphisms within the NET gene on alcohol-related phenotypes in alcohol dependent and non-dependent populations. The long-term objective of this research is to develop more efficacious treatment interventions for alcohol abuse and dependence. Hypothesis 1: It is hypothesized that subjects who receive 40, 60 or 80 mg/day of atomoxetine for 5 days will demonstrate significantly less alcohol-elicited craving than subjects who receive a placebo. Hypothesis 2: It is hypothesized that subjects who receive 40, 60 or 80 mg/day of atomoxetine for 5 days will be less sensitive to the acute effects of alcohol (subjective intoxication) than subjects who receive a placebo.
Interventions
- DRUG Atomoxetine, Strattera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408589
The ClinicalTrials.gov registry entry for NCT01408589 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine, Strattera is the first listed.
NCT01408589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408589 about?
NCT01408589 is a clinical study titled "A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol". This two-stage study will examine the effects of a 5 day course of atomoxetine (placebo, 40, 60 or 80 mg/day; Strattera) (a selective NE transporter (NET) inhibitor) on alcohol-elicited craving and sensitivity to alcohol. The novelty of this study is that of atomoxetine and the fact that it targets ...
What is the current status of trial NCT01408589?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2005-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT01408589?
The interventions under investigation include: Atomoxetine, Strattera (DRUG).
Who is sponsoring clinical trial NCT01408589?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.